SCHEMBL22902849

SCHEMBL22902849

COc1cccc2cc(C(N)=O)c3ncnn3c12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 1/20 0.45
ADORA2B P29275 1/20 0.45
ADORA1 P30542 1/20 0.45
ALDH1A1 P00352 3/20 0.40
KMT2A Q03164 1/20 0.40
AURKA O14965 4/20 0.40
MET P08581 4/20 0.40
KDR P35968 4/20 0.40
TEK Q02763 4/20 0.40
AURKB Q96GD4 4/20 0.40
ABL1 P00519 1/20 0.40
LCK P06239 1/20 0.40
LYN P07948 1/20 0.40
KDM4E B2RXH2 2/20 0.39
HPGD P15428 2/20 0.39
HSD17B10 Q99714 1/20 0.39
PDE4B Q07343 2/20 0.39
JAK2 O60674 1/20 0.39
JAK1 P23458 1/20 0.39
TYK2 P29597 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22902446 0.84 MAPT (0.44) ALDH1A1KMT2AKDM4EHPGDHSD17B10
SCHEMBL29522789 0.84 MAPT (0.44) ALDH1A1KMT2AKDM4EHPGDHSD17B10
SCHEMBL22902757 0.82 LCK (0.42) ALDH1A1LCKKDM4EHPGDHSD17B10
SCHEMBL22902860 0.81 ADORA2A (0.45) ADORA2AADORA2BADORA1ALDH1A1KMT2A
SCHEMBL22902857 0.81 ADORA2A (0.45) ADORA2AADORA2BADORA1ALDH1A1KMT2A
SCHEMBL22902398 0.78 SYK (0.45) ADORA2AADORA2BADORA1ALDH1A1KMT2A
SCHEMBL22902434 0.76 IRAK4 (0.52) IRAK4
SCHEMBL22902800 0.76 ADORA2A (0.45) ADORA2AADORA2BADORA1ALDH1A1KMT2A
SCHEMBL22902774 0.76 ADORA2A (0.45) ADORA2AADORA2BADORA1ALDH1A1KMT2A
SCHEMBL29790129 0.75 IKBKB (0.42) ALDH1A1KMT2AKDM4EHPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12286428-B2 Tricyclic heteroaryl compounds useful as IRAK4 inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2025-04-29 US disclosed
CN-114423757-B Tricyclic heteroaryl compounds useful as IRAK4 inhibitors 百时美施贵宝公司 2024-07-02 CN disclosed
EP-3999508-B1 TRICYCLIC HETEROARYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2023-08-30 EP disclosed
EP-3999508-B1 TRICYCLIC HETEROARYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2023-08-30 EP disclosed
US-20220259205-A1 TRICYCLIC HETEROARYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2022-08-18 US disclosed
CN-114423757-A Tricyclic heteroaryl compounds useful as IRAK4 inhibitors 百时美施贵宝公司 2022-04-29 CN disclosed
WO-2021011724-A1 TRICYCLIC HETEROARYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2021-01-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220259205-A1 TRICYCLIC HETEROARYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS IRAK4, IRAK1, IRAK3 ADORA2A 2175/4885ADORA2B 2455/4885ADORA1 1365/4885
US-12286428-B2 Tricyclic heteroaryl compounds useful as IRAK4 inhibitors IRAK4, IRAK1, IRAK3 ADORA2A 2175/4885ADORA2B 2455/4885ADORA1 1365/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.